TY - JOUR
T1 - Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium
AU - Camidge, Ross
AU - Gaspar, Laurie
AU - Goss, Glennwood
AU - Kelly, Karen
AU - Ramalingam, Suresh
AU - Reckamp, Karen
AU - Simon, George
AU - Tsao, Ming
AU - West, Howard
AU - Herbst, Roy
AU - Johnson, David
AU - Bunn, Paul
AU - Govindan, Ramaswamy
N1 - Funding Information:
Dr. Ramalingam has received honorarium from Genentech and Lilly to serve on the advisory board. Dr. Bunn has consulted for Bachringer Ingelheim, Genentech/Roche, OSI, BMS, Imclone, Eli Lilly and Sanofi-Aventis. UC Denver has contracts with all these and Dr. Bunn is involved in these contracts, Dr. Reckcamp has received honorarium and travel expenses from Eli Lilly and Genentech for the speaker's bureau. Dr. Govindan has served on the lecture bureau for Lilly and Genentech and has consulted for Imclone and Pfizer. Dr. Goss has received research funding from AstraZeneca and Roche Pharmaceuticals. He has received honorium from Roche, AstraZeneca and Pfizer for service on scientific advisory boards.
PY - 2009/7
Y1 - 2009/7
N2 - Lung cancer is the leading cause of cancer-related death in the United States. Outcomes for patients with lung cancer have reached a plateau with cytotoxic chemotherapy. Lung cancer remains very much at the vanguard of the new revolution in cancer therapy using molecular targets. Although striking improvements in survival have been observed in the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and in a subset of breast cancer using this approach, the impact of targeted therapies in lung cancer is quite modest. Along with advances in imaging and cancer genomics, there is now considerable optimism that the pace of progress in the treatment of lung cancer will accelerate in the next 10 years. As has been the custom for the past 8 years, leading experts in the biology, diagnosis and treatment of lung cancer met for three days to discuss current areas of research and future directions. This summary provides a brief snapshot of the discussions held at the 8th Annual Meeting on Targeted Therapies for Lung Cancer sponsored by the International Association for the Study of Lung Cancer in Santa Monica in early February 2008.
AB - Lung cancer is the leading cause of cancer-related death in the United States. Outcomes for patients with lung cancer have reached a plateau with cytotoxic chemotherapy. Lung cancer remains very much at the vanguard of the new revolution in cancer therapy using molecular targets. Although striking improvements in survival have been observed in the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and in a subset of breast cancer using this approach, the impact of targeted therapies in lung cancer is quite modest. Along with advances in imaging and cancer genomics, there is now considerable optimism that the pace of progress in the treatment of lung cancer will accelerate in the next 10 years. As has been the custom for the past 8 years, leading experts in the biology, diagnosis and treatment of lung cancer met for three days to discuss current areas of research and future directions. This summary provides a brief snapshot of the discussions held at the 8th Annual Meeting on Targeted Therapies for Lung Cancer sponsored by the International Association for the Study of Lung Cancer in Santa Monica in early February 2008.
KW - Genomics
KW - Lung cancer
KW - Molecularly targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=68549140259&partnerID=8YFLogxK
U2 - 10.1097/JTO.0b013e3181a9a03b
DO - 10.1097/JTO.0b013e3181a9a03b
M3 - Article
C2 - 19550249
AN - SCOPUS:68549140259
SN - 1556-0864
VL - 4
SP - 930
EP - 935
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 7
ER -